Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-10 09:52 am Purchase | 2024-03-31 | 13G | C4 Therapeutics, Inc. CCCC | STATE STREET CORP STT | 7,153,280 10.430% | 7,153,280 (New Position) | Filing History |
| 2024-03-08 1:11 pm Sale | 2024-03-08 | 13G | C4 Therapeutics, Inc. CCCC | WASATCH ADVISORS LP | 5,516,718 8.000% | -1,622,231 (-22.72%) | Filing History |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 2,558,480 5.200% | -366,773 (-12.54%) | Filing History |
| 2024-02-14 09:21 am Purchase | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | LYNX1 CAPITAL MANAGEMENT LP | 3,134,396 6.400% | 12,177 (+0.39%) | Filing History |
| 2024-02-14 07:35 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | RTW Investments, LP | 0 0.000% | -2,819,472 (Position Closed) | Filing History |
| 2024-02-09 1:04 pm Purchase | 2024-02-09 | 13G | C4 Therapeutics, Inc. CCCC | WASATCH ADVISORS LP | 7,138,949 14.500% | 1,363,251 (+23.60%) | Filing History |
| 2024-02-05 10:24 am Purchase | 2024-01-26 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,555,996 5.200% | 720,000 (+39.22%) | Filing History |
| 2024-02-02 09:34 am Sale | 2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 1,835,996 3.700% | -626,024 (-25.43%) | Filing History |
| 2024-01-12 4:01 pm Purchase | 2024-01-04 | 13G | C4 Therapeutics, Inc. CCCC | Betta Investment (Hong Kong) Ltd. | 5,567,928 8.100% | 5,567,928 (New Position) | Filing History |
| 2024-01-04 4:15 pm Purchase | 2024-01-03 | 13G | C4 Therapeutics, Inc. CCCC | Point72 Asset Management, L.P. | 2,676,696 5.400% | 2,676,696 (New Position) | Filing History |
| 2023-12-26 4:30 pm Purchase | 2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC | RA Capital Management, L.P. | 4,878,000 9.900% | 4,878,000 (New Position) | Filing History |
| 2023-12-22 4:05 pm Purchase | 2023-12-14 | 13G | C4 Therapeutics, Inc. CCCC | Commodore Capital LP | 3,800,000 7.700% | 3,800,000 (New Position) | Filing History |
| 2023-11-13 4:55 pm Purchase | 2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC | LYNX1 CAPITAL MANAGEMENT LP | 3,122,219 6.300% | 3,122,219 (New Position) | Filing History |
| 2023-07-25 4:40 pm Purchase | 2023-07-19 | 13G | C4 Therapeutics, Inc. CCCC | Integrated Core Strategies (Asia) Pte. Ltd. | 2,370,504 4.800% | 2,370,504 (New Position) | Filing History |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 2,086,563 4.300% | -1,534,570 (-42.38%) | Filing History |
| 2023-06-12 4:13 pm Sale | 2023-05-31 | 13G | C4 Therapeutics, Inc. CCCC | ArrowMark Colorado Holdings LLC | 1,493,450 3.040% | -4,309,421 (-74.26%) | Filing History |
| 2023-04-14 5:07 pm Purchase | 2023-04-13 | 13G | C4 Therapeutics, Inc. CCCC | Soleus Capital Master Fund, L.P. | 2,462,020 5.000% | 2,462,020 (New Position) | Filing History |
| 2023-02-14 5:30 pm Purchase | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | ArrowMark Colorado Holdings LLC | 5,802,871 11.850% | 389,143 (+7.19%) | Filing History |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 2,925,253 6.000% | -1,159,545 (-28.39%) | Filing History |
| 2023-02-14 10:08 am Purchase | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | RTW Investments, LP | 2,819,472 5.800% | 324,507 (+13.01%) | Filing History |